Grace Therapeutics, Inc.
GRCE
$2.27
-$0.03-1.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.98% | 6.03% | -1.82% | -0.23% | 7.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.58% | -32.52% | -21.90% | 11.57% | 47.90% |
| Operating Income | 33.58% | 32.52% | 21.90% | -11.57% | -47.90% |
| Income Before Tax | 25.64% | 57.44% | 33.87% | 6.75% | 13.06% |
| Income Tax Expenses | 46.86% | 66.84% | 39.28% | -9.18% | -74.62% |
| Earnings from Continuing Operations | 18.55% | 55.28% | 32.63% | 9.91% | 25.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.55% | 55.28% | 32.63% | 9.91% | 25.56% |
| EBIT | 33.58% | 32.52% | 21.90% | -11.57% | -47.90% |
| EBITDA | 33.60% | 32.54% | 21.91% | -11.55% | -47.99% |
| EPS Basic | 44.31% | 69.29% | 42.70% | 28.69% | 41.49% |
| Normalized Basic EPS | 48.77% | 69.78% | 43.04% | 25.15% | 22.46% |
| EPS Diluted | 44.31% | 69.29% | 42.70% | 28.69% | 41.49% |
| Normalized Diluted EPS | 48.77% | 69.78% | 43.04% | 25.15% | 22.46% |
| Average Basic Shares Outstanding | 38.24% | 37.81% | 25.87% | 27.21% | 25.76% |
| Average Diluted Shares Outstanding | 38.24% | 37.81% | 25.87% | 27.21% | 25.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |